Twenty years after the first implantation by Alain Cribier and his team, transcatheter aortic valve implantation (TAVI) has demonstrated its efficacy and safety in patients with symptomatic severe aortic stenosis with high, intermediate, and even low surgical risk. Consequently, its indications have expanded widely over the years, with the improvement of structural devices, operator’s experience, procedural techniques, and post-procedural management.
[...]
Uncertainty remains about the selection of the optimal device in patients with severe aortic stenosis undergoing TAVR. Larger observational studies and randomized controlled trials with adequate statistical power and long-term follow-up are warranted to further evaluate this issue.
